September 12, 2007 - Rochester Medical Corp. said a newly published clinical study demonstrates the effectiveness of the company’s proprietary infection control technology with nitrofurazone-impregnated urinary catheters.
The newly released September issue of the “Annals of Internal Medicine” presents results of a randomized, double-blind, controlled clinical trial involving 212 adult patients at Denmark’s Copenhagen Trauma Center. The study concluded nitrofurazone-impregnated urinary catheters reduced the incidence of catheter-associated bacteriuria and funguria in adult trauma patients, reducing the need to change or prescribe new antimicrobial therapy.
The catheters used in the study were manufactured by Rochester Medical. The control catheter was an all-silicone Foley catheter. The study was conducted by Jakob Stensballe, Ph.D; Michael Tvede, M.D.; Dagnia Looms, Ph.D; Freddy Knudsen Lippert, M.D.; Benny Dahl, DMSc; Else Tonnesen, DMSc; and Lars Simon Rasmussen, Ph.D.
Dr. Stensballe and his colleagues showed serious infections can be significantly reduced by use of advanced release-NF technology.
For more information: www.rocm.com
July 25, 2024 
